Overview

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
Phase:
Phase 2
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Gemcitabine